Commercialisation

One of the main strategic objectives of the CSCB is to advance knowledge in the chemical sciences of synthesis and chemical biology in order to discover and develop novel therapeutic agents for medicine. Once novel agents are discovered, commercialisation is a natural progression to further develop their potential as medicines.

The CSCB is committed to fostering entrepreneurship, supporting technology transfer and developing strong partnerships with industry. Researchers work closely with NovaUCD, which is the innovation and technology centre at UCD, to facilitate successful commercialisation of the research programmes. Weekly clinics by NovaUCD staff are held in the UCD Conway Institute of Biomolecular and Biomedical Research.

The CSCB principal investigators Dr Raphael Darcy, Dr Declan Gilheany and Professor Paul Engel are involved in three campus companies.

Cytrea

Cytrea is a biotechnology company which focuses on the development of modified cyclodextrins as delivery systems for the controlled release and targeted delivery of bioactive entities with the emphasis being on biopharmaceuticals.
Cytrea was founded in 2001 by Dr Raphael Darcy of UCD’s School of Chemistry and Chemical Biology and Professor Caitríona O’Driscoll of UCC’s Department of Pharmacy. The company is based on the UCD biotechnology campus.

Services provided by the company involve contract research in the application of Cytrea cyclodextrins, for example in the formulations for delivery of a drug or in the controlled release of nutrients in cell culture technology.

For further details about the company please contact Dr Raphael Darcy - email raphael.darcy@ucd.ie

Celtic Catalysts

Celtic Catalysts is a life-sciences and process optimisation company, which is focused on the niche area of chiral catalysis. The company is commercialising chiral technology which has been developed over the past ten years in UCD’s School of Chemistry and Chemical Biology.

The executive team comprises Brian Elliott (Chief Executive Officer), Dr Declan Gilheany (Chief Scientific Officer) and Dr Brian Kelly (Director of Business Development). Dr Declan Gilheany, a co-founder of the company, has been working for over 20 years in the area of asymmetric synthesis and is the author of numerous publications in this field.

Celtic Catalysts has developed a key piece of intellectual property which enables it to make a vast array (thousands) of chiral catalysts of a type that has previously been demonstrated as being industrially viable. Celtic Catalysts also has the ability to screen these catalysts in a systematic and automated way to ascertain which ones suit a particular industrial process for the pharmaceutical or fine chemical industries.

On November 21st 2005, Celtic Catalysts was awarded a European Commission grant under the prestigious Marie Curie scheme. The grant is worth just under €1 million over 3 years.

Further details about the company can be found on their website at http://www.celticcatalysts.com/

Enzolve

Enzolve is a biotechnology company which is focused on the commercialisation of novel enzyme products arising from UCD research particularly in the area of protein engineering. Enzolve provides novel enzyme-based solutions for example in the areas of diagnostics, synthesis and food.

The promoters of Enzolve are Professor Paul Engel and Dr Suren Aghajanian and the company is located in the Conway Institute of Biomolecular and Biomedical Research.

Further details about the company can be found on their website at
http://www.ucd.ie/nova/clientco/enzolve.html